Minimal residual disease in breast cancer: in blood veritas
Giulia Siravegna1, Alberto Bardelli2
1Authors' Affiliations: Department of Oncology, University of Turin; Candiolo Cancer Institute-FPO, IRCCS, Turin; and FIRC Institute of Molecular Oncology (IFOM), Milan, ItalyAuthors' Affiliations: Department of Oncology, University of Turin; Candiolo Cancer Institute-FPO, IRCCS, Turin; and FIRC Institute of Molecular Oncology (IFOM), Milan, Italy.
Abstract:
A blood-based molecular test might direct recommendations for systemic therapies in patients with early-stage breast cancer undergoing surgery with curative intent. A new study suggests that droplet digital PCR (ddPCR) can be used to detect cancer-specific DNA alterations in plasma with sensitivity suitable for monitoring minimal residual disease.
